Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 3/20 | 0.33 |
| ▸ | LDHB | P07195 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28211238 | 0.87 | GABRA1 (0.45) | GABRA1GABRB2TDP1KDM4EMEN1 | |
| SCHEMBL2305327 | 0.82 | GABRA1 (0.42) | GABRA1GABRB2TYK2SLC22A12TDP1 | |
| SCHEMBL326586 | 0.80 | GABRA1 (0.56) | GABRA1GABRB2MAPK1TDP1MEN1 | |
| SCHEMBL158739 | 0.80 | GABRA1 (0.40) | GABRA1GABRB2SLC22A12KDM4EPTGS2 | |
| SCHEMBL28113846 | 0.80 | PDE2A (0.33) | MAPK1TDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL14256901 | 0.79 | PTGS2 (0.39) | TYK2SLC22A12KDM4EMEN1KMT2A | |
| SCHEMBL10613040 | 0.79 | GABRA1 (0.68) | GABRA1GABRB2MAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL75037 | 0.79 | GABRA1 (0.43) | GABRA1GABRB2TDP1KDM4EMEN1 | |
| SCHEMBL374747 | 0.79 | MAPK1 (0.39) | GABRA1GABRB2MAPK1TDP1P2RX7 | |
| SCHEMBL1513863 | 0.76 | CYP3A4 (0.47) | GABRA1GABRB2MAPK1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461034-B1 | SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A DRUG OR FOR DIAGNOSIS, AND DRUG CONTAINING SUBSTITUTED IMIDAZOLIDINES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-11-22 | — | — | EP | claimed |
| EP-1461034-A1 | SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A DRUG OR FOR DIAGNOSIS, AND DRUG CONTAINING SUBSTITUTED IMIDAZOLIDINES | Aventis Pharma Deutschland GmbH (DE) | 2004-09-29 | — | — | EP | claimed |
| WO-2003053434-A1 | SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A DRUG OR FOR DIAGNOSIS, AND DRUG CONTAINING SUBSTITUTED IMIDAZOLIDINES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-03 | — | — | WO | claimed |
| CN-107849816-B | Method for treating paperboard and paper media and related treated paperboard and paper media | 巴斯夫欧洲公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-106232667-B | Polyiso-ureas | 巴斯夫欧洲公司 | 2020-01-07 | — | — | CN | disclosed |
| US-20180298557-A1 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED TREATED PAPERBOARDS AND PAPER MEDIA | BASF CORPORATION | 2018-10-18 | — | — | US | disclosed |
| EP-3107946-B1 | A POLYISO-UREA | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-9982083-B2 | Polyiso-urea | BASF SE (DE) | 2018-05-29 | — | — | US | disclosed |
| EP-3298194-A2 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED PAPERBOARDS AND PAPER MEDIA | BASF SE (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170058075-A1 | POLYISO-UREA | BASF SE (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170058074-A1 | POST-MODIFIED POLYCARBODIIMIDES | BASF SE (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20050004198-A1 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1461034-A1 | SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A DRUG OR FOR DIAGNOSIS, AND DRUG CONTAINING SUBSTITUTED IMIDAZOLIDINES | Aventis Pharma Deutschland GmbH (DE) | 2004-09-29 | — | — | EP | disclosed |
| US-6686384-B2 | 2-ANILINOPHENYL-SUBSTITUTED; INHIBITION OF THE NA+/H+ EXCHANGER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-10-09 | — | — | US | disclosed |
| US-20030187045-A1 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-1341770-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003053434-A1 | SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A DRUG OR FOR DIAGNOSIS, AND DRUG CONTAINING SUBSTITUTED IMIDAZOLIDINES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-03 | — | — | WO | disclosed |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002046169-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187045-A1 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic | CHRM1, ARG2, ACHE | GABRA1 1949/4885GABRB2 3244/4885TYK2 4209/4885 |
| US-20050004198-A1 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them | ACHE, CHRM1, CHRM3 | GABRA1 1594/4885GABRB2 2077/4885TYK2 4394/4885 |
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | ABCB11, ATP1A2, ATP1A1 | GABRA1 359/4885GABRB2 652/4885TYK2 4528/4885 |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | ABCB11, ATP1A2, ATP1A1 | GABRA1 359/4885GABRB2 652/4885TYK2 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.